Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one cares - Anyone can just post where they sold. As usual you never post entries and randomly post exists
Intraday shorts toast - definition of a short squeeze was today’s action
SA better start laying off their lousy authors
Yep sold a second time at $22.00 as I said I would sell over $20.00. GL everyone. It was a fun long day.
Now the question is where will they price a PO cause we all can smell it
You already sold. Move on
Trust me that is not the case. Play it wisely up or down. I will be selling again over 20.00 soon.
It will continue to be unstobbleable for at least a few more days... Either way this is a long term hold.
SOLY over $17.50 so far in afterhours. This one has been unstoppable.
Oh Oh, Clay and his short friends are showing up. Hopefully we burn them good tomorrow.
* * $SOLY Video Chart 05-28-2019 * *
Link to Video - click here to watch the technical chart video
Holy moly! SOLY
See you at $20 tomorrow:) been here since ipo
It could easily run higher but dang that was a fun run so far today!
Good decision
What a fun day we have had so far in SOLY. Out for now at just under $12.00.
Spanking Alfalfa is comedic. It’s what happens when you have no actual authors or writers on staff and pay for blog posts.
Can't stop laughing at seeking Alpha rag shorter's getting their butts burned to a crisp, the seeking rag shorts blown out of the water with a huge short squeeze loss, should never trust what crap those guys print, as in this case they print total BS article from white Diamond research trash.
Are you still in it?
Afternoon bull run. Did the same thing after the morning retracement a few days ago
Soliton Initiated Clinical Trials for Treatment of Cellulite in Humans
Source: PR Newswire (US)
HOUSTON, April 1, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today summarized its efforts to conduct a proof of concept clinical trial for the treatment of cellulite based on Institutional Review Board ("IRB") approval of the study. The study was initiated after positive results in animal studies indicated the potential for a higher-energy version of its acoustic shockwave technology to affect the factors contributing to the formation of cellulite.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). (PRNewsfoto/Soliton, Inc.)
The study treated each thigh of five patients (n=10) with a higher-energy version of Soliton's acoustic shockwave device with the intent to evaluate safety and efficacy in the treatment of cellulite. The study is designed to evaluate results at both the 12-week and 26-week timepoints from initial treatment in order to assess both near-term and long-term effects.
----------------------------
Join our more than 200K fans here to follow the Company: https://soly-investors.com
----------------------------
"Our preclinical data led us to believe we could have a significant impact on the reduction of cellulite," commented Dr. Chris Capelli, Soliton's President and CEO. "This is especially significant since our technology should represent a non-invasive, pain free treatment that requires no anesthesia and involves no bruising, discomfort or downtime. If we are right, we believe this could be a major breakthrough in the treatment of cellulite."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. Both products are investigational and are not available for sale in the United States.
For more information about the Company, please visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton's acoustic shockwave device to reduce cellulite in the proof of concept clinical trial. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Item 1A. Risk Factors" in the Form 10-K for the year ended December 31, 2018 we filed with the SEC and updated from time to time in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700
soly@lythampartners.com
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/soliton-initiated-clinical-trials-for-treatment-of-cellulite-in-humans-300821569.html
SOURCE Soliton, Inc.
Copyright 2019 PR Newswire
Soliton Files 510(k) with FDA for its Rapid Acoustic Pulse Device. See press release.
Soliton Partners with Sanmina, a Global Medical Device Manufacturer
HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Soliton, Inc., (NASDAQ: SOLY) (''Soliton'' or the ''Company''), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (''MD Anderson''), highlights the Company's important partnership with Sanmina Corporation to advance its acoustic shockwave technology into the commercialization phase in preparation for product launch.
------------------------
Join our more than 208K fans here to follow the Company: https://soly-investors.com
------------------------
Sanmina is a global contract electronics manufacturer and one of the world's largest medical device manufacturers. Under the agreement, Sanmina will provide the design and testing to advance Soliton's RAP device for use in future clinical trials and eventually to lay the foundation for a commercial launch of the Company's products.
''Working with Sanmina in this commercialization phase not only provides us with world-class quality and documentation,'' commented Dr. Chris Capelli, Soliton's CEO, ''but we also believe it will make for a smoother transition to manufacturing, which we expect to begin here in the US later this year.''
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. Both products are investigational and are not available for sale in the United States.
For more information about the Company, please visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton to receive clearance to market its devices and the ability of Sanmina Corporation to successfully commercialize Soliton's technology. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700
soly@lythampartners.com
SOURCE: Soliton, Inc.
Soliton Receives FDA Approval for Small Business Designation
The Company qualifies for reduced or waived fees for medical device submissions with the FDA
HOUSTON, TX / ACCESSWIRE / March 4, 2019 / Soliton, Inc., (NASDAQ: SOLY) (''Soliton'' or the ''Company''), a medical device company with a novel and proprietary platform technology licensed from The University of Texas M.D. on behalf of the MD Anderson Cancer Center (''MD Anderson''), today announced that it has received notice from the U.S. Food and Drug Administration ("FDA") that the Company has qualified for the ''Small Business'' designation under the Medical Device User Fee Amendments (''MDUFA''). As a Small Business under the MDUFA, Soliton qualifies for a reduce or waived fee for medical device submissions made during the fiscal year 2019.
------------------------
Join our more than 208K fans here to follow the Company: https://soly-investors.com
------------------------
Dr. Christopher Capelli, president and CEO of Soliton, said, ''We are pleased to have qualified for Small Business status allowing us to receive reduced or waived fees for our FDA submissions. We appreciate the opportunity to submit device applications for review and approval at more favorable rates. In certain submissions, the savings could be dramatic. This helps us to operate more efficiently. Our plan is to is to submit our Rapid Acoustic Pulse (''RAP'') device for tattoo removal for premarket clearance with the FDA under our new status in the near future.''
The MDUFA rates cover a number of submissions that are routinely made to the FDA for review and approval. The rate table assigns fees for the fiscal year - which ends on September 30, 2019 - for the application type submitted for review along with the Standard Fee and the Small Business fee for companies that qualify for the designation.
The table of 2019 MDUFA rates can be accessed at: https://www.fda.gov/ForIndustry/UserFees/MedicalDeviceUserFee/ucm615142.htm
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first planned commercial product will use rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The Company believes this ''Soliton'' method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods. Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.
For more information about the Company, please visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton RAP to accelerate tattoo fading or fat removal and/or to reduce cellulite, and whether future clinical trials related to the acceleration of existing fat removal technologies and cellulite are successful. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700
soly@lythampartners.com
Soliton's RAP Device Received Institutional Review Board Approval of Non-Significant Risk Designation
HOUSTON, TX / ACCESSWIRE / March 8, 2019 / Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), discusses that their RAP device received institutional review board ("IRB") approval as a non-significant risk device. Subsequent to receiving this status, the Company conducted several human clinical trials to study the use of the RAP device to accelerate tattoo fading and initiated a proof-of-concept trial in humans for the reduction of cellulite.
Soliton's RAP device accelerates tattoo removal in part by providing dermal clearing of laser-generated vacuoles during laser treatment. This designation by the IRB allows the Company to use its device in human clinical trials.
The Institutional Review Board (IRB) is an FDA registered constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve, require modifications (to secure approval), or disapprove research. This group review serves an important role in the protection of the rights and welfare of human research subjects.
"The NSR designation makes it very straight forward for us to conduct clinical trials with our technology," commented Dr. Chris Capelli, Soliton's President and CEO. " This applies not only to the clinical data we are presenting to the FDA with regard to accelerating tattoo removal, but potential future indications like cellulite reduction. We believe this allows us to move more quickly in developing Soliton RAP."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first planned commercial product will use rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing its Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners. Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.
For more information about the Company, please visit: http://www.soliton.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton RAP to receive FDA clearance, as well as reduce the appearance of cellulite in humans. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Joe Dorame, Joe Diaz& Robert Blum
Lytham Partners, LLC
602-889-9700
soly@lythampartners.com
SOURCE: Soliton, Inc.
Released March 8, 2019
HOUSTON, TX / ACCESSWIRE / March 12, 2019 / Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that President and CEO Chris Capelli, Executive Chairman Walter Klemp, CFO Lori Bisson and other team members, will ring the Closing Bell of the Nasdaq Stock Market on Tuesday, March 19, 2019 at 4:00 p.m. Eastern.
Join our more than 208K fans here to follow the Company: https://soly-investors.com
Dr. Christopher Capelli, president and CEO of Soliton, said, "We are honored to ring the Nasdaq closing bell in celebration of our recent IPO. We are excited about the opportunities ahead in the burgeoning tattoo removal market for our leading-edge Rapid Acoustic Pulse ("RAP") technology, which is capable of delivering treatment for tattoo removal in a more efficient, less painful and cost saving manner. In ongoing animal studies, a new verion of the Company's acoustic pulse technology is also demonstrating real potential in the reduction of cellulite. We believe there are significant opportunities in these markets as well. I would like to thank the entire Soliton team for their tireless efforts and for the confidence of our shareholders as we work to execute on our strategic growth plan."
The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, 43rd and Broadway, in New York.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
87
|
Created
|
03/13/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |